Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium Difficile Toxin A), MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium Difficile Toxin A and Toxin B) in Patients Receiving Antibiotic Therapy for Clostridium Difficile Infection (MODIFY I)
Status: Enrolling
Updated:  8/11/2014
Clinical Research Facility
mi
from
Rapid City, SD
A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium Difficile Toxin A), MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium Difficile Toxin A and Toxin B) in Patients Receiving Antibiotic Therapy for Clostridium Difficile Infection (MODIFY I)
Status: Enrolling
Updated: 8/11/2014
Clinical Research Facility
mi
from
Rapid City, SD
Click here to add this to my saved trials
A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium Difficile Toxin A), MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium Difficile Toxin A and Toxin B) in Patients Receiving Antibiotic Therapy for Clostridium Difficile Infection (MODIFY I)
Status: Enrolling
Updated:  8/11/2014
Clinical Research Facility
mi
from
Houston, TX
A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium Difficile Toxin A), MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium Difficile Toxin A and Toxin B) in Patients Receiving Antibiotic Therapy for Clostridium Difficile Infection (MODIFY I)
Status: Enrolling
Updated: 8/11/2014
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium Difficile Toxin A), MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium Difficile Toxin A and Toxin B) in Patients Receiving Antibiotic Therapy for Clostridium Difficile Infection (MODIFY I)
Status: Enrolling
Updated:  8/11/2014
Clinical Research Facility
mi
from
Salt Lake City, UT
A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium Difficile Toxin A), MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium Difficile Toxin A and Toxin B) in Patients Receiving Antibiotic Therapy for Clostridium Difficile Infection (MODIFY I)
Status: Enrolling
Updated: 8/11/2014
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium Difficile Toxin A), MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium Difficile Toxin A and Toxin B) in Patients Receiving Antibiotic Therapy for Clostridium Difficile Infection (MODIFY I)
Status: Enrolling
Updated:  8/11/2014
Clinical Research Facility
mi
from
Richmond, VA
A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium Difficile Toxin A), MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium Difficile Toxin A and Toxin B) in Patients Receiving Antibiotic Therapy for Clostridium Difficile Infection (MODIFY I)
Status: Enrolling
Updated: 8/11/2014
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium Difficile Toxin A), MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium Difficile Toxin A and Toxin B) in Patients Receiving Antibiotic Therapy for Clostridium Difficile Infection (MODIFY I)
Status: Enrolling
Updated:  8/11/2014
Clinical Research Facility
mi
from
Everett, WA
A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium Difficile Toxin A), MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium Difficile Toxin A and Toxin B) in Patients Receiving Antibiotic Therapy for Clostridium Difficile Infection (MODIFY I)
Status: Enrolling
Updated: 8/11/2014
Clinical Research Facility
mi
from
Everett, WA
Click here to add this to my saved trials
A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium Difficile Toxin A), MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium Difficile Toxin A and Toxin B) in Patients Receiving Antibiotic Therapy for Clostridium Difficile Infection (MODIFY I)
Status: Enrolling
Updated:  8/11/2014
Clinical Research Facility
mi
from
Seattle, WA
A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium Difficile Toxin A), MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium Difficile Toxin A and Toxin B) in Patients Receiving Antibiotic Therapy for Clostridium Difficile Infection (MODIFY I)
Status: Enrolling
Updated: 8/11/2014
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium Difficile Toxin A), MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium Difficile Toxin A and Toxin B) in Patients Receiving Antibiotic Therapy for Clostridium Difficile Infection (MODIFY I)
Status: Enrolling
Updated:  8/11/2014
Clinical Research Facility
mi
from
Seattle, WA
A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium Difficile Toxin A), MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium Difficile Toxin A and Toxin B) in Patients Receiving Antibiotic Therapy for Clostridium Difficile Infection (MODIFY I)
Status: Enrolling
Updated: 8/11/2014
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Bordetella Pertussis Carriage in College-aged Students
Bordetella Pertussis Carriage in College-aged Students
Status: Enrolling
Updated:  8/12/2014
University of Virginia Health System
mi
from
Charlottesville, VA
Bordetella Pertussis Carriage in College-aged Students
Bordetella Pertussis Carriage in College-aged Students
Status: Enrolling
Updated: 8/12/2014
University of Virginia Health System
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Comparative Efficacy and Safety of Two Ciprofloxacin 0.3% and Dexamethasone 0.1% Formulations in Subjects With Acute Otitis Externa
A Phase 3, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study of the Comparative Efficacy and Safety of EXL CDOS in Subjects With Acute Otitis Externa
Status: Enrolling
Updated:  8/12/2014
Piedmont Ear Nose and Throat Associates, PA
mi
from
Winston Salem, NC
Comparative Efficacy and Safety of Two Ciprofloxacin 0.3% and Dexamethasone 0.1% Formulations in Subjects With Acute Otitis Externa
A Phase 3, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study of the Comparative Efficacy and Safety of EXL CDOS in Subjects With Acute Otitis Externa
Status: Enrolling
Updated: 8/12/2014
Piedmont Ear Nose and Throat Associates, PA
mi
from
Winston Salem, NC
Click here to add this to my saved trials
A Single Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Debio 1450 in Healthy Subjects
Status: Enrolling
Updated:  8/15/2014
Early Phase Clinical Unit
mi
from
Baltimore, MD
A Single Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Debio 1450 in Healthy Subjects
Status: Enrolling
Updated: 8/15/2014
Early Phase Clinical Unit
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Debio 1450 in Healthy Subjects
Status: Enrolling
Updated:  8/15/2014
Early Phase Clinical Unit
mi
from
Baltimore, MD
A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Debio 1450 in Healthy Subjects
Status: Enrolling
Updated: 8/15/2014
Early Phase Clinical Unit
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Louisville, KY
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Orange, CA
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
San Diego, CA
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Atlanta, GA
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Indianapolis, IN
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Morgantown, WV
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Morgantown, WV
Click here to add this to my saved trials
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Shreveport, LA
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Shreveport, LA
Click here to add this to my saved trials
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Boston, MA
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Jackson, MS
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Jackson, MS
Click here to add this to my saved trials
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Omaha, NE
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Akron, OH
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Akron, OH
Click here to add this to my saved trials
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Cleveland, OH
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Toledo, OH
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Toledo, OH
Click here to add this to my saved trials
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Austin, TX
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Houston, TX
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Houston, TX
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Little Rock, AR
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of P. Aeruginosa in Cystic Fibrosis Subjects Aged From 3 Months to Less Than 7 Years
Status: Enrolling
Updated:  8/29/2014
Novartis Investigative Site
mi
from
Long Beach, CA
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of P. Aeruginosa in Cystic Fibrosis Subjects Aged From 3 Months to Less Than 7 Years
Status: Enrolling
Updated: 8/29/2014
Novartis Investigative Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of P. Aeruginosa in Cystic Fibrosis Subjects Aged From 3 Months to Less Than 7 Years
Status: Enrolling
Updated:  8/29/2014
Novartis Investigative Site
mi
from
Detroit, MI
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of P. Aeruginosa in Cystic Fibrosis Subjects Aged From 3 Months to Less Than 7 Years
Status: Enrolling
Updated: 8/29/2014
Novartis Investigative Site
mi
from
Detroit, MI
Click here to add this to my saved trials
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of P. Aeruginosa in Cystic Fibrosis Subjects Aged From 3 Months to Less Than 7 Years
Status: Enrolling
Updated:  8/29/2014
Novartis Investigative Site
mi
from
Morristown, NJ
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of P. Aeruginosa in Cystic Fibrosis Subjects Aged From 3 Months to Less Than 7 Years
Status: Enrolling
Updated: 8/29/2014
Novartis Investigative Site
mi
from
Morristown, NJ
Click here to add this to my saved trials
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of P. Aeruginosa in Cystic Fibrosis Subjects Aged From 3 Months to Less Than 7 Years
Status: Enrolling
Updated:  8/29/2014
Novartis
mi
from
New York, NY
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of P. Aeruginosa in Cystic Fibrosis Subjects Aged From 3 Months to Less Than 7 Years
Status: Enrolling
Updated: 8/29/2014
Novartis
mi
from
New York, NY
Click here to add this to my saved trials
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of P. Aeruginosa in Cystic Fibrosis Subjects Aged From 3 Months to Less Than 7 Years
Status: Enrolling
Updated:  8/29/2014
Novartis
mi
from
Pittsburgh, PA
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of P. Aeruginosa in Cystic Fibrosis Subjects Aged From 3 Months to Less Than 7 Years
Status: Enrolling
Updated: 8/29/2014
Novartis
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of P. Aeruginosa in Cystic Fibrosis Subjects Aged From 3 Months to Less Than 7 Years
Status: Enrolling
Updated:  8/29/2014
Novartis Investigative Site
mi
from
Nashville, TN
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of P. Aeruginosa in Cystic Fibrosis Subjects Aged From 3 Months to Less Than 7 Years
Status: Enrolling
Updated: 8/29/2014
Novartis Investigative Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Comparison of "Wet Suction" Technique to Contemporary "Dry Suction" Technique Using a 22 Gauge Needle for EUS FNA
Comparison of "Wet Suction" Technique to Contemporary "Dry Suction" Technique Using a 22 Gauge Needle for EUS FNA of Solid Lesions. A Randomized, Prospective, Blinded, and Controlled Trial
Status: Enrolling
Updated:  9/3/2014
University of Minnesota Medical Center
mi
from
Minneapolis, MN
Comparison of "Wet Suction" Technique to Contemporary "Dry Suction" Technique Using a 22 Gauge Needle for EUS FNA
Comparison of "Wet Suction" Technique to Contemporary "Dry Suction" Technique Using a 22 Gauge Needle for EUS FNA of Solid Lesions. A Randomized, Prospective, Blinded, and Controlled Trial
Status: Enrolling
Updated: 9/3/2014
University of Minnesota Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Comparison of "Wet Suction" Technique to Contemporary "Dry Suction" Technique Using a 22 Gauge Needle for EUS FNA
Comparison of "Wet Suction" Technique to Contemporary "Dry Suction" Technique Using a 22 Gauge Needle for EUS FNA of Solid Lesions. A Randomized, Prospective, Blinded, and Controlled Trial
Status: Enrolling
Updated:  9/3/2014
Aurora St.Luke's Medical Center
mi
from
Milwaukee, WI
Comparison of "Wet Suction" Technique to Contemporary "Dry Suction" Technique Using a 22 Gauge Needle for EUS FNA
Comparison of "Wet Suction" Technique to Contemporary "Dry Suction" Technique Using a 22 Gauge Needle for EUS FNA of Solid Lesions. A Randomized, Prospective, Blinded, and Controlled Trial
Status: Enrolling
Updated: 9/3/2014
Aurora St.Luke's Medical Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Self-Obtained Vaginal Swabs for Chlamydia and Gonorrhea Testing
Self-Obtained Vaginal Swabs for Chlamydia and Gonorrhea Testing: Concurrence in Non-Clinical Settings vs. Clinical Settings
Status: Enrolling
Updated:  9/4/2014
University of California - San Francisco
mi
from
San Francisco, CA
Self-Obtained Vaginal Swabs for Chlamydia and Gonorrhea Testing
Self-Obtained Vaginal Swabs for Chlamydia and Gonorrhea Testing: Concurrence in Non-Clinical Settings vs. Clinical Settings
Status: Enrolling
Updated: 9/4/2014
University of California - San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Evaluation of CL Detect™ Rapid Test to Detect Cutaneous Leishmaniasis
Pivotal Trials: Evaluation of a Rapid Diagnostic Device, CL Detect™ Rapid Test, for the Diagnosis of Cutaneous Leishmaniasis in the United States
Status: Enrolling
Updated:  9/5/2014
Mount Sinai School of Medicine
mi
from
New York, NY
Evaluation of CL Detect™ Rapid Test to Detect Cutaneous Leishmaniasis
Pivotal Trials: Evaluation of a Rapid Diagnostic Device, CL Detect™ Rapid Test, for the Diagnosis of Cutaneous Leishmaniasis in the United States
Status: Enrolling
Updated: 9/5/2014
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Impact of Prevnar 13 on Ear Infections in Children
Postmarketing Observational Study Of The Impact Of Prevnar 13 (Pneumococcal 13 Valent Conjugate Vaccine) On Otitis Media In Children
Status: Enrolling
Updated:  9/10/2014
Arkansas Children's Hospital
mi
from
Little Rock, AR
Impact of Prevnar 13 on Ear Infections in Children
Postmarketing Observational Study Of The Impact Of Prevnar 13 (Pneumococcal 13 Valent Conjugate Vaccine) On Otitis Media In Children
Status: Enrolling
Updated: 9/10/2014
Arkansas Children's Hospital
mi
from
Little Rock, AR
Click here to add this to my saved trials
Impact of Prevnar 13 on Ear Infections in Children
Postmarketing Observational Study Of The Impact Of Prevnar 13 (Pneumococcal 13 Valent Conjugate Vaccine) On Otitis Media In Children
Status: Enrolling
Updated:  9/10/2014
Children's Hospital of Los Angeles - University of Southern California School of Medicine
mi
from
Los Angeles, CA
Impact of Prevnar 13 on Ear Infections in Children
Postmarketing Observational Study Of The Impact Of Prevnar 13 (Pneumococcal 13 Valent Conjugate Vaccine) On Otitis Media In Children
Status: Enrolling
Updated: 9/10/2014
Children's Hospital of Los Angeles - University of Southern California School of Medicine
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Impact of Prevnar 13 on Ear Infections in Children
Postmarketing Observational Study Of The Impact Of Prevnar 13 (Pneumococcal 13 Valent Conjugate Vaccine) On Otitis Media In Children
Status: Enrolling
Updated:  9/10/2014
Rady Children's Hospital - San Diego
mi
from
San Diego, CA
Impact of Prevnar 13 on Ear Infections in Children
Postmarketing Observational Study Of The Impact Of Prevnar 13 (Pneumococcal 13 Valent Conjugate Vaccine) On Otitis Media In Children
Status: Enrolling
Updated: 9/10/2014
Rady Children's Hospital - San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Impact of Prevnar 13 on Ear Infections in Children
Postmarketing Observational Study Of The Impact Of Prevnar 13 (Pneumococcal 13 Valent Conjugate Vaccine) On Otitis Media In Children
Status: Enrolling
Updated:  9/10/2014
Brenner Children's Hospital - Wake Forest University School of Medicine
mi
from
Winston-Salem, NC
Impact of Prevnar 13 on Ear Infections in Children
Postmarketing Observational Study Of The Impact Of Prevnar 13 (Pneumococcal 13 Valent Conjugate Vaccine) On Otitis Media In Children
Status: Enrolling
Updated: 9/10/2014
Brenner Children's Hospital - Wake Forest University School of Medicine
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Impact of Prevnar 13 on Ear Infections in Children
Postmarketing Observational Study Of The Impact Of Prevnar 13 (Pneumococcal 13 Valent Conjugate Vaccine) On Otitis Media In Children
Status: Enrolling
Updated:  9/10/2014
Nationwide Children's Hospital - Ohio State University of Medicine and Public Health
mi
from
Columbus, OH
Impact of Prevnar 13 on Ear Infections in Children
Postmarketing Observational Study Of The Impact Of Prevnar 13 (Pneumococcal 13 Valent Conjugate Vaccine) On Otitis Media In Children
Status: Enrolling
Updated: 9/10/2014
Nationwide Children's Hospital - Ohio State University of Medicine and Public Health
mi
from
Columbus, OH
Click here to add this to my saved trials
Impact of Prevnar 13 on Ear Infections in Children
Postmarketing Observational Study Of The Impact Of Prevnar 13 (Pneumococcal 13 Valent Conjugate Vaccine) On Otitis Media In Children
Status: Enrolling
Updated:  9/10/2014
Children's Hospital of Pittsburgh - University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Impact of Prevnar 13 on Ear Infections in Children
Postmarketing Observational Study Of The Impact Of Prevnar 13 (Pneumococcal 13 Valent Conjugate Vaccine) On Otitis Media In Children
Status: Enrolling
Updated: 9/10/2014
Children's Hospital of Pittsburgh - University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Impact of Prevnar 13 on Ear Infections in Children
Postmarketing Observational Study Of The Impact Of Prevnar 13 (Pneumococcal 13 Valent Conjugate Vaccine) On Otitis Media In Children
Status: Enrolling
Updated:  9/10/2014
Texas Children's Hospital - Feigin Center
mi
from
Houston, TX
Impact of Prevnar 13 on Ear Infections in Children
Postmarketing Observational Study Of The Impact Of Prevnar 13 (Pneumococcal 13 Valent Conjugate Vaccine) On Otitis Media In Children
Status: Enrolling
Updated: 9/10/2014
Texas Children's Hospital - Feigin Center
mi
from
Houston, TX
Click here to add this to my saved trials
Impact of Prevnar 13 on Ear Infections in Children
Postmarketing Observational Study Of The Impact Of Prevnar 13 (Pneumococcal 13 Valent Conjugate Vaccine) On Otitis Media In Children
Status: Enrolling
Updated:  9/10/2014
Children's Memorial Hospital
mi
from
Chicago, IL
Impact of Prevnar 13 on Ear Infections in Children
Postmarketing Observational Study Of The Impact Of Prevnar 13 (Pneumococcal 13 Valent Conjugate Vaccine) On Otitis Media In Children
Status: Enrolling
Updated: 9/10/2014
Children's Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals
Phase 1 Evaluation of the Optimal Interval Between Priming With a Live Influenza A Vaccine H7N9 (6-2) AA ca Recombinant (A/Anhui/1/2013 (H7N9) x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Influenza H7N9 Disease Followed by Boost With a Non-adjuvanted Inactivated H7N9 Influenza Vaccine
Status: Enrolling
Updated:  10/16/2014
Johns Hopkins Bayview Medical Center
mi
from
Baltimore, MD
Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals
Phase 1 Evaluation of the Optimal Interval Between Priming With a Live Influenza A Vaccine H7N9 (6-2) AA ca Recombinant (A/Anhui/1/2013 (H7N9) x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Influenza H7N9 Disease Followed by Boost With a Non-adjuvanted Inactivated H7N9 Influenza Vaccine
Status: Enrolling
Updated: 10/16/2014
Johns Hopkins Bayview Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Chest Ultrasound of ER Patients With Cough or SOB
Prospective Evaluation With Ultrasound of Emergency Department Patients Presenting With Cough or Dyspnea
Status: Enrolling
Updated:  10/17/2014
University of Washington Medical Center
mi
from
Seattle, WA
Chest Ultrasound of ER Patients With Cough or SOB
Prospective Evaluation With Ultrasound of Emergency Department Patients Presenting With Cough or Dyspnea
Status: Enrolling
Updated: 10/17/2014
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated:  10/21/2014
Clinical Research Facility
mi
from
Appleton, WI
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Clinical Research Facility
mi
from
Appleton, WI
Click here to add this to my saved trials
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated:  10/21/2014
Clinical Research Facility
mi
from
Bear Creek, WI
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Clinical Research Facility
mi
from
Bear Creek, WI
Click here to add this to my saved trials